TELA BioTELA
TELA
About: TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Employees: 209
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
6% more funds holding
Funds holding: 47 [Q4 2024] → 50 (+3) [Q1 2025]
6.45% less ownership
Funds ownership: 68.63% [Q4 2024] → 62.17% (-6.45%) [Q1 2025]
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
63% less capital invested
Capital invested by funds: $81.6M [Q4 2024] → $30M (-$51.6M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
18%
upside
Avg. target
$5.33
214%
upside
High target
$7
312%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Canaccord Genuity Caitlin Cronin | 312%upside $7 | Buy Maintained | 21 Mar 2025 |
Citizens Capital Markets David Turkaly | 312%upside $7 | Market Outperform Maintained | 21 Mar 2025 |
Piper Sandler Matt O'Brien | 18%upside $2 | Neutral Downgraded | 21 Mar 2025 |
Financial journalist opinion
Based on 4 articles about TELA published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grant of an option to purchase 75,000 shares of its common stock and restricted stock units covering 30,000 shares of its common stock to Jim Hagen, the Company's Senior Vice President – Strategic Commercial Operations, with a grant date of June 2, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Mr. Hagen's employment compensation and were granted as an inducement material to his acceptance of employment with TELA Bio.
Neutral
GlobeNewsWire
1 week ago
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
Based on market research, inguinal hernia repair is the most common type of hernia repair Based on market research, inguinal hernia repair is the most common type of hernia repair
Neutral
GlobeNewsWire
1 week ago
TELA Bio Appoints Jeffrey Blizard as President
Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth
Neutral
GlobeNewsWire
3 weeks ago
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the 2025 Jefferies Global Healthcare Conference.
Neutral
Seeking Alpha
1 month ago
TELA Bio, Inc. (TELA) Q1 2025 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Louisa Smith - The Gilmartin Group Antony Koblish - Co-founder, President & Chief Executive Office Roberto Cuca - Chief Operating Officer & Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Michael Sarcone - Jefferies David Turkaly - Citizens JMP Operator Good afternoon ladies and gentlemen and welcome to the TELA Bio First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode.
Neutral
GlobeNewsWire
1 month ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
Negative
Zacks Investment Research
1 month ago
TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.23 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
TELA Bio to Announce First Quarter 2025 Financial Results
MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Neutral
Seeking Alpha
2 months ago
TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Greg Chodaczek - The Gilmartin Group Antony Koblish - Co-founder, President and Chief Executive Office Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity David Turkaly - Citizens Matt O'Brien - Piper Sandler Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Neutral
Zacks Investment Research
2 months ago
TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.53 per share a year ago.
Charts implemented using Lightweight Charts™